⁍ The study will also test Humanigen’s experimental drug lenzilumab with remdesivir.
⁍ Risankizumab and lenzilumab belong to a class of drugs known as monoclonal antibodies.
– President Trump may have been treated with an antibody drug earlier this month, but a new study aims “to identify as quickly as possible the experimental therapeutics that demonstrate the most clinical promise as COVID-19 treatments and move them into larger-scale testing,” Anthony Fauci, director of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, says in a statement, per Reuters. The study will evaluate two antibody treatments: AbbVie’s psoriasis drug risankizumab along with Gilead Sciences’ antiviral remdesivir, compared to a placebo and remdesivir. The study will also test Humanigen’s experimental drug lenzilumab with remdesivir, compared to placebo and remdesivir. “The goal here is to identify as quickly as possible the experimental therapeutics that demonstrate the most clinical promise as COVID-19 treatments and move them into larger-scale testing,” Fauci says.
Source: https://www.reuters.com/article/us-health-coronavirus-nih/nih-starts-clinical-trial-testing-antibody-treatments-in-covid-19-patients-idUSKBN26Y2F1